<DOC>
	<DOCNO>NCT01079897</DOCNO>
	<brief_summary>This study evaluate efficacy topical use ectoine-formulation EHK02-01 compare Atopiclair . Patients examine visit 2 ( baseline visit ) . The patient topically apply EHK02-01 Zarzenda® twice daily two symmetric lesional area 28 day . Response therapy record visit .</brief_summary>
	<brief_title>Efficacy Safety Ectoine-containing Cream Treatment Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Glycyrrhetinic Acid</mesh_term>
	<criteria>Female male individual 18 65 year good general health diagnose atopic dermatitis ≥ 6 month , active stage ( active stage mean severity measure overall IGAScore 1 4 ) At least two comparable area stable atopic eczema bilateral symmetric correspond side extremity body ( except head genital area ) , least 10 cm² , modify , objective local SCORAD test area &gt; 5 Both lesional area interest must difference modify , objective local SCORAD ≤ 3 Willingness adhere schedule investigation , concomitant therapy prohibition , restriction , treatment regimen procedure describe CIP Written inform consent participate trial , prior investigation relate procedure , indicate understand purpose clinical investigation A patient childbearing potential agrees use contraceptive method duration investigation accord CPMP/ICH 286/95 note 3 Patients selfreported pregnant , nurse plan pregnancy clinical investigation Patients skin disease investigator 's opinion may interfere conduct study evaluation result ( e.g . psoriasis ) Patients known malignancy Presence disease and/or condition and/or history disease and/or condition accord investigator may interfere conduct investigation evaluation result ( abnormal laboratory value , chronic inflammatory disease , immunosuppressive disease , autoimmune disease , liver kidney disease , severe infectious disease ) Patients respect washout period prior clinical investigation Vaccination within 6 day prior enrolment study . Patients know allergy ingredient test product Patients known substance abuse ( drug alcohol ) problem within previous 12 month Patients participate another clinical trial participate another clinical trial within last 30 day prior first day investigation Patients involve organization clinical investigation Patients way dependant investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Ectoine</keyword>
	<keyword>Treatment</keyword>
	<keyword>Atopiclair</keyword>
	<keyword>Medical device</keyword>
</DOC>